Internal Medicine, Endocrinology, Diabetes, & Metabolism · Redding, CA
NPI
1831266345
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1555 East St, Suite 300
Redding, CA, 96001
Phone (530) 229-1844
Groups this clinician bills Medicare through
Medicare paid, 2024
$210K
3,098 services
Medicare patients, 2024
1,081
Average age 73
Drug cost, 2024
$3.8M
7,174 prescriptions
Company payments, 2025
$1,074
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mitchell S Akman was code 99213 (office e&m - established), 1,320 times for 721 patients. In total Mitchell S Akman billed 3,098 services in 17 codes, and Medicare paid $210K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-01-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,320 | 721 | $63.28 | $84K |
| 99214 Office E&M - Established | Office | 858 | 542 | $83.59 | $72K |
| 95251 Test - Miscellaneous | Office | 344 | 148 | $25.54 | $8,786 |
| 99205 Office E&M - New | Office | 199 | 199 | $153.80 | $31K |
| G0008 Administration of influenza virus vaccine | Office | 171 | 171 | $32.91 | $5,628 |
| 90653 Vaccine Product | Office | 149 | 149 | $49.00 | $7,301 |
| 90661 Vaccine Product | Office | 25 | 25 | $36.11 | $903 |
| 79005 Radiation Treatment Planning | Office | 13 | 13 | $65.22 | $848 |
By year: 2022 $201K for 2,891 services; 2023 $225K for 3,023 services; 2024 $210K for 3,098 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 11 | 11 | $2.22 | $24.4 |
Medicare prescription drug claims, 2024
In 2024, the drug Mitchell S Akman prescribed most often to Medicare patients was Levoxyl (Levothyroxine Sodium), with 1,555 prescriptions and refills. In total Mitchell S Akman wrote 7,174 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levoxyl Levothyroxine Sodium | 1,555 | 4,166 | 383 | $69K |
| Synthroid Levothyroxine Sodium | 656 | 1,596 | 147 | $71K |
| Ozempic Semaglutide | 588 | 1,107 | 133 | $1.0M |
| Atorvastatin Calcium Generic | 403 | 1,162 | 135 | $4,136 |
| Jardiance Empagliflozin | 268 | 602 | 77 | $337K |
| Rosuvastatin Calcium Generic | 252 | 708 | 83 | $7,720 |
| Pioglitazone Hcl Generic | 249 | 670 | 70 | $4,103 |
| Metformin Hcl Er Metformin Hcl | 241 | 667 | 77 | $3,829 |
| Ezetimibe Generic | 162 | 478 | 55 | $9,198 |
| Calcitriol Generic | 154 | 416 | 45 | $8,212 |
| Metformin Hcl Generic | 147 | 405 | 40 | $2,176 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 126 | 291 | 43 | $26K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 126 | 330 | 55 | $13K |
| Testosterone Generic | 112 | 201 | 27 | $22K |
| Glimepiride Generic | 107 | 305 | 32 | $943 |
Brand drugs: 4,253 claims; generic drugs: 2,694 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mitchell S Akman $1,074 ($1,074 in general payments such as food, travel and fees) from 11 companies. The largest payer was Novo Nordisk Inc with $281.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 16 | $281 |
| Amgen Inc. AMGN | 22 | $269 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $140 |
| Tandem Diabetes Care, Inc. TNDM | 4 | $129 |
| Lilly USA, LLC LLY | 4 | $95.79 |
| Ascendis Pharma Endocrinology Inc ASND | 2 | $57 |
| Abbvie Inc. ABBV | 1 | $27.34 |
| Esperion Therapeutics, Inc. ESPR | 1 | $21.66 |
| Beta Bionics, Inc. BBNX | 2 | $19.25 |
| Corcept Therapeutics CORT | 1 | $18.64 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.